Founder Securities(SH:601901) Mei Ri Jing Ji Xin Wen·2025-07-30 01:08Group 1 - Several securities firms, including CITIC Securities and Guosen Securities, have quickly launched trading permissions for the new Sci-Tech Growth Board, indicating high market interest in this new segment [1] - Investors need to meet a threshold of 500,000 yuan in assets and have two years of investment experience to participate, which helps filter qualified investors and manage risks [1] - The introduction of the Sci-Tech Growth Board enhances the multi-tiered capital market structure, providing financing channels for tech innovation companies, which is expected to boost overall market vitality and innovation momentum in the long term [1] Group 2 - On July 29, Founder Securities announced that its major shareholder, China Cinda Asset Management, did not execute its planned share reduction, which is seen as a positive signal for the company's long-term value [2] - The unchanged shareholding of China Cinda, which holds 593 million shares (7.2% of total shares), may help stabilize market sentiment and alleviate investor concerns about share dilution [2] - This situation is likely to support the brokerage sector and enhance confidence in financial stocks, contributing to market stability [2] Group 3 - In July, over 900 billion yuan worth of new funds were issued, indicating a recovery in market confidence [3] - The increase in stock and bond fund shares, driven by the equity market and innovative products like the Sci-Tech Bond ETF, reflects a growing risk appetite among investors [3] - The decline in mixed fund shares suggests a preference for clearer directional investments, which may lead to increased activity in related sectors and improved market liquidity [3] Group 4 - Seven ETFs have achieved "doubling" performance this year, with the top performer, Huatai-PB Hang Seng Innovation Drug ETF, showing a 107.67% return [4] - The strong performance of Hong Kong innovation drug ETFs highlights the robust market interest in the innovative drug sector, potentially attracting more capital into the healthcare segment [4] - Continued advancements in innovative drug research and supportive policies are key drivers for the pharmaceutical industry, with high-performing ETFs likely to enhance investor risk appetite [4]